GlassScriptPhysician profile
Jessica Keyes
NPI 1295442929
$4,525.04
in general payments reported to CMS, 2019-2025
32 companies · $1,819 in 2025
The $1,819 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,179 · 2024: $1,527 · 2025: $1,819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,525.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $697.90 | 2023-2025 | Jardiance |
| Amgen INC. | $545.39 | 2023-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $540.01 | 2023-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $346.90 | 2023-2025 | Farxiga |
| Novo Nordisk INC | $295.97 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Lexicon Pharmaceuticals, INC. | $181.12 | 2023-2024 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $160.93 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $159.17 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $151.30 | 2023-2024 | Xarelto |
| Pfizer INC. | $142.47 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $134.04 | 2025 | Verquvo |
| Alnylam Pharmaceuticals INC. | $119.89 | 2024-2025 | Onpattro |
| Kiniksa Pharmaceuticals, LTD. | $118.00 | 2023 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $113.48 | 2023-2024 | |
| Philips North America LLC | $110.16 | 2024-2025 | Ecc Solutions, (Ck4) Mcot, Mcot |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $103.75 | 2024 | Arcalyst |
| Edwards Lifesciences Corporation | $94.92 | 2025 | Evoque |
| Boston Scientific Corporation | $77.95 | 2023-2025 | Watchman Flx, Watchman Access System |
| Scpharmaceuticals INC. | $59.30 | 2023-2024 | |
| Shockwave Medical, INC | $49.71 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Lilly USA, LLC | $46.45 | 2024-2025 | Zepbound, Jardiance |
| Abiomed | $37.50 | 2025 | |
| Esperion Therapeutics, INC. | $35.62 | 2023 | Nexletol |
| Cvrx, INC. | $32.40 | 2024 | Barostim Neo System |
| Vital Connect, INC | $26.72 | 2023 | Vitalpatch Rtm |
| Inspire Medical Systems, INC. | $25.13 | 2025 | Inspire |
| Cardiovascular Systems INC. | $24.80 | 2023 | Diamondback Coronary |
| Medtronic, INC. | $24.17 | 2023 | Cobalt Dr Mri Surescan |
| Thrombolex, INC. | $22.42 | 2025 | Bashir Endovascular Catheter |
| Surmodics, INC. | $17.64 | 2025 | Pounce Venous Thrombectomy System, Sublime Microcatheter, 018, 200cm, Straight, Pounce Thrombectomy System |
| Azurity Pharmaceuticals, INC. | $15.26 | 2023 | Edarbi |
| Angiodynamics, INC. | $14.57 | 2023 | Alphavac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Keyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.